Fractyl Health Announces Potent Preclinical Results for RJVA-002, Paving Way for First-in-Human Trials of Novel Gene Therapy for Obesity and Type 2 Diabetes
Reuters
Oct 07
<a href="https://laohu8.com/S/GUTS">Fractyl Health</a> Announces Potent Preclinical Results for RJVA-002, Paving Way for First-in-Human Trials of Novel Gene Therapy for Obesity and Type 2 Diabetes
Fractyl Health Inc. has announced potent new preclinical results from RJVA-002, a dual GIP/GLP-1 gene therapy candidate for obesity, developed under its Rejuva® platform. In a translational obesity model, a single administration of RJVA-002 achieved approximately 30% weight loss at five weeks, with weight loss not yet plateaued. The results suggest the potential for significant and durable weight loss from a one-time intervention. RJVA-002 is the second candidate from Fractyl's gene therapy platform, which aims to enable long-term remission of obesity and type 2 diabetes (T2D) by reprogramming pancreatic islet cells to produce metabolic hormones. Results from ongoing studies at longer time points and with additional metabolic measurements will be presented at an upcoming scientific congress. The company's first Rejuva candidate, RJVA-001, is expected to enter first-in-human clinical trials for T2D in 2026, pending regulatory authorization.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fractyl Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9541066-en) on October 07, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.